Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase

Jiakuan Liu, Tian Fang, Meiqian Li, Yuting Song, Junzun Li, Zesheng Xue, Jiaxuan Li, Dandan Bu, Wei Liu, Qinghe Zeng, Yidan Zhang, Shifeng Yun, Ruimin Huang, Jun YanScientific 2019 · DOI

Abstract

Benign prostatic hyperplasia (BPH) is one of the most common diseases in the urinary system of elderly men. Pao extract is an herbal preparation of the bark of the Amazon rainforest tree Pao Pereira (Geissospermum vellosii), which was reported to inhibit prostate cancer cell proliferation. Herein we investigated the therapeutic potential of Pao extract against BPH development in a testosterone-induced BPH rat model. The administration of testosterone induced the prostate enlargement, compared with the sham operated group with vehicle treatment. The BPH/Pao group showed reduced prostate weight comparable with BPH/finasteride group. Notably, Pao treatment did not significantly reduce body weights and sperm number of rats, compared with the control group. Furthermore, Pao extract treatment reduced the proliferative index in prostate glands and testosterone-induced expression levels of AR, as well as androgen-associated proteins such as SRD5A1 and PSA. Moreover, Pao extract and its active component, flavopereirine, induced cytotoxicity on human prostate epithelial RWPE-1 cells in a dose- and time- dependent manner with G2/M arrest. Consistently, Pao extract and flavopereirine suppressed the expression levels of SRD5A1, AR and PSA, respectively. Together, these data demonstrated that Pao extract suppresses testosterone-induced BPH development through inhibiting AR activity and expression, and suggested that Pao extract may be a promising and relative safe agent for BPH.

Introduction

Benign Prostatic Hyperplasia (BPH) is a near-universal condition in aging men, characterized by the non-cancerous overgrowth of the prostate gland. This growth constricts the urethra, leading to lower urinary tract symptoms (LUTS) that significantly impact quality of life. The current "gold standard" treatments involve 5α-reductase inhibitors (5αRIs) like finasteride, which block the conversion of testosterone into the more potent dihydrotestosterone (DHT). However, these drugs are frequently associated with adverse side effects, including erectile dysfunction, loss of libido, and reduced sperm counts. This study investigates Pao Pereira extract as a potential botanical alternative that could offer similar therapeutic efficacy with a milder side-effect profile.

Methods

The study employed a dual-track approach using both animal models and human cell lines:

  • In Vivo (Rat Model): Male Sprague-Dawley rats were castrated and then administered testosterone propionate (TP) to induce BPH. The rats were divided into four groups: Sham (control), BPH/Vehicle, BPH/Finasteride (positive control), and BPH/Pao extract (20 mg/kg).
  • In Vitro (Cell Culture): Researchers used RWPE-1 cells (non-malignant human prostate epithelial cells) to test the effects of both the whole Pao extract and its primary active alkaloid, flavopereirine (Fla).
  • Analytical Techniques: Tissue morphology was assessed via H&E staining, while proliferation markers (PCNA) and AR levels were tracked using Immunohistochemistry (IHC). Western Blotting quantified protein expression (SRD5A1, AR, PSA), and flow cytometry was used for cell cycle analysis.

Results

Experimental timeline and effects of Pao extract on prostate weight and index in BPH rats.

Attenuation of Prostate Enlargement

The administration of Pao extract significantly reduced the wet weight and "prostate index" (prostate weight relative to body weight) in BPH rats, performing similarly to the clinical standard, finasteride. Histological analysis confirmed that treatment reversed testosterone-induced thickening of the prostatic epithelial layer and restored the lumen area within the gland.

Molecular Mechanisms and Safety

One of the most significant findings was the extract's safety profile regarding reproductive health. While finasteride significantly reduced sperm counts in the rats, the Pao extract group showed no significant difference from the control group. Molecularly, the extract specifically targeted SRD5A1 (5α-reductase type 1), preventing the formation of DHT. It also suppressed the expression of the androgen receptor (AR) and Prostate-Specific Antigen (PSA).

In human RWPE-1 cells, the extract and flavopereirine induced a specific arrest in the G2/M phase of the cell cycle, effectively halting the over-proliferation characteristic of BPH.

Discussion and Conclusion

This study demonstrates that Pao Pereira extract effectively suppresses testosterone-induced BPH development by inhibiting the 5α-reductase/AR pathway. Its ability to reduce prostate enlargement without the typical side effect of reduced sperm count makes it a promising candidate for further clinical research.

However, limitations remain. The study administered the extract simultaneously with testosterone, demonstrating a preventative effect rather than a therapeutic reversal of established BPH. Furthermore, while the results in human cell lines are encouraging, clinical trials are necessary to establish appropriate human dosages and long-term safety profiles. Future research may also explore the extract's impact on other pathways, such as NFκB or Wnt/β-catenin, to fully elucidate its mechanism of action.

Summary updated

Abstract

Benign prostatic hyperplasia (BPH) is one of the most common diseases in the urinary system of elderly men. Pao extract is an herbal preparation of the bark of the Amazon rainforest tree Pao Pereira (Geissospermum vellosii), which was reported to inhibit prostate cancer cell proliferation. Herein we investigated the therapeutic potential of Pao extract against BPH development in a testosterone-induced BPH rat model. The administration of testosterone induced the prostate enlargement, compared with the sham operated group with vehicle treatment. The BPH/Pao group showed reduced prostate weight comparable with BPH/finasteride group. Notably, Pao treatment did not significantly reduce body weights and sperm number of rats, compared with the control group. Furthermore, Pao extract treatment reduced the proliferative index in prostate glands and testosterone-induced expression levels of AR, as well as androgen-associated proteins such as SRD5A1 and PSA. Moreover, Pao extract and its active component, flavopereirine, induced cytotoxicity on human prostate epithelial RWPE-1 cells in a dose- and time- dependent manner with G2/M arrest. Consistently, Pao extract and flavopereirine suppressed the expression levels of SRD5A1, AR and PSA, respectively. Together, these data demonstrated that Pao extract suppresses testosterone-induced BPH development through inhibiting AR activity and expression, and suggested that Pao extract may be a promising and relative safe agent for BPH.
BibTeX
@inproceedings{liu2019pao,
  author = {Jiakuan Liu and Tian Fang and Meiqian Li and Yuting Song and Junzun Li and Zesheng Xue and Jiaxuan Li and Dandan Bu and Wei Liu and Qinghe Zeng and Yidan Zhang and Shifeng Yun and Ruimin Huang and Jun Yan},
  title = {{Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase}},
  booktitle = {Scientific},
  year = {2019},
  doi = {10.1038/s41598-019-56145-z},
}
Figure